

CURRENT PERSPECTIVES IN HAEMATOLOGICAL MALIGNANCIES

Wednesday 10th October 2018

The Lighthouse, 11 Mitchell Lane, Glasgow G1 3NU

Chairs: Dr Anne Parker (*Glasgow*) and Professor Graham Jackson (*Newcastle*)

09.30 *Registration*

10.15 The challenges of CML resistance
(5 mins Q)

Professor Mhairi Copland
Queen Elizabeth Hospital, Glasgow

10.50 CLL - heading for a cure?
(5 mins Q)

Dr George Follows
Addenbrooke's Hospital, Cambridge

11.25 *Coffee*

11.50 Continuous therapy in myeloma - the future
(5 mins Q)

Professor Graham Jackson
NCCC, Newcastle

12.30 *Lunch*

13.00 **DEBATES:**

ECHELON 1 : Brentuximab should be used first line
in advanced Hodgkin lymphoma

Chair: Dr Andrew McMillan, *Nottingham*
For: Professor Tim Illidge, *Manchester*
Against: Dr Wendy Osborne, *Newcastle*

GALLIUM : Obinutuzumab, not rituximab, should
be used first line for patients with symptomatic
follicular lymphoma

Chair: Professor Tim Illidge, *Manchester*
For: Dr Wendy Osborne, *Newcastle*
Against: Dr Andrew McMillan, *Nottingham*

14.30 *Coffee*

14.50 **Workshop: AML**

- The new drugs we have available
- The trials
- Patient based discussion

Dr Steve Knapper
University Hospital of Wales

Dr Mike Dennis
Christie Hospital, Manchester

Dr Dominic Culligan
Aberdeen Royal Infirmary

16.20 *Close*

REGISTRATION:

STANDARD (until 25 th September)	LATE (from 26 th September)
Consultants: £72 Trainees/Nurses: £60 20 free places available for Trainees/Nurses	£108

Fees inclusive of VAT at 20%

Online registration now open at www.hartleytaylor.co.uk

To check availability for one of the free places or for any further information, please contact
alex@hartleytaylor.co.uk or telephone 01565 621967

This meeting is kindly sponsored by:



The sponsors have had no influence over the content of the agenda or speaker selection